Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)

BACKGROUND: The prevention of coronavirus disease 2019 (COVID-19) in vulnerable populations is a global health priority. EVADE was a phase 2/3 multicenter, double-blind, randomized, placebo-controlled trial of adintrevimab, an extended–half-life monoclonal antibody, for postexposure (PEP) and pre-ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Ison, Michael G, Weinstein, Debra F, Dobryanska, Marta, Holmes, Anna, Phelan, Anne-Marie, Li, Yong, Gupta, Deepali, Narayan, Kristin, Tosh, Kazima, Hershberger, Ellie, Connolly, Lynn E, Yalcin, Ilker, Campanaro, Ed, Hawn, Pamela, Schmidt, Pete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368201/
https://www.ncbi.nlm.nih.gov/pubmed/37496612
http://dx.doi.org/10.1093/ofid/ofad314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368201/
https://www.ncbi.nlm.nih.gov/pubmed/37496612
http://dx.doi.org/10.1093/ofid/ofad314

Ejemplares similares